Collagen Assembly in Tissue-Engineered Cartilage

组织工程软骨中的胶原蛋白组装

基本信息

  • 批准号:
    8234165
  • 负责人:
  • 金额:
    $ 30.33万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2014-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The ability of cartilage to act as a shock absorber depends on the quality of the collagen fibrillar network that frames cartilage. This network is made up of three different types of collagen (types II, IX and XI) assembled and precisely cross-linked together into heteropolymers. Despite many advances in the field of cartilage tissue engineering, a continuous challenge has been to increase the collagen content of bioengineered cartilage to levels observed in native articular cartilage. Since the collagen heteropolymer is a crucial template of the mature fibrillar architecture and for the ongoing stability of the mature tissue, we hypothesize that a cross-linked template of type II/IX/XI collagen heterofibrils must sequentially assemble in the matrix of newly forming cartilage to allow type II collagen fibril growth, an increased collagen content and so achieve the biomechanical properties of functional articular cartilage. Whether correct cross-linked assemblies of the minor collagen template (types IX and XI) with type II collagen form in neo-cartilage, is not well characterized. Our goal is to determine if a collagen network typical of hyaline cartilage is assembled in chondrocyte based and mesenchymal stem cell based bio-engineered tissues. Since the minor collagens regulate the organization of the network, (e.g., collagen fibril diameter modulated by type XI/V collagen), fingerprinting the pattern of collagen inter-type cross-linking can provide a screen for normal matrix assembly and a valuable tool in understanding the sequence of events in the fibrillogenesis of the type II/IX/XI collagen fibril in adult mesenchymal stem cells undergoing chondrogenesis. The aim is to use Western blot, ELISA, LC-mass spectrometry, and other advanced methods in protein chemistry to establish a molecular fingerprint of the collagen fibril assembly and a set of parameters to use as a biomarker to better evaluate the cross-linked collagen network in normal and engineered cartilage. The ultimate goal is to validate proteomic methods to use as an outcome measure of tissue engineered cartilage that has the collagen content, quality and structural properties of articular cartilage needed to transplant into cartilage defects. The goals also include laying the foundation for evaluating the changing quality of cartilage produced as a healing response. PUBLIC HEALTH RELEVANCE: The ability of cartilage to act as a shock absorber depends on the quality of the collagen heterofibrillar network that frames cartilage. In arthritis, this collagen network is broken down leading to a loss of normal joint function and severe pain. The goal of this study is to develop and authenticate a biomarker to monitor if this collagen heterofibrillar network assembled in bioengineered cartilage is typical of normal cartilage.
描述(申请人提供):软骨作为减震器的能力取决于构成软骨的胶原纤维网络的质量。这个网络由三种不同类型的胶原蛋白(II型、II型和XI型)组装而成,并精确地交叉连接在一起形成杂多聚合物。尽管软骨组织工程领域取得了许多进展,但将生物工程软骨的胶原含量提高到天然关节软骨的水平一直是一个持续的挑战。由于胶原异质聚合物是成熟的纤维结构和成熟组织的持续稳定性的重要模板,我们假设II/IX/XI型胶原异质纤维的交联型模板必须顺序地组装在新形成的软骨基质中,以允许II型胶原纤维生长,增加胶原含量,从而获得功能性关节软骨的生物力学性能。在新生软骨中,次要胶原模板(IX和XI型)是否与II型胶原形成正确的交联组装,目前还没有很好的描述。我们的目标是确定在以软骨细胞和间充质干细胞为基础的生物工程组织中是否组装了典型的透明软骨的胶原网络。由于次胶原调节网络的组织(例如,由XI/V型胶原调节的胶原纤维直径),指纹图谱可以为正常的基质组装提供筛查,也是了解正在进行软骨形成的成人间充质干细胞II/IX/XI型胶原纤维形成过程中的一系列事件的有价值的工具。本研究的目的是利用蛋白质化学中的蛋白质印迹、酶联免疫吸附试验、液质联用等先进方法,建立胶原纤维组装的分子指纹图谱和一系列参数作为生物标志物,以更好地评价正常和工程化软骨中的交联型胶原网络。最终目标是验证蛋白质组学方法作为组织工程软骨的结果衡量标准,该组织工程软骨具有移植到软骨缺损处所需的关节软骨的胶原含量、质量和结构特性。目标还包括为评估作为愈合反应产生的软骨质量的变化奠定基础。 与公共健康相关:软骨作为减震器的能力取决于构成软骨的胶原蛋白异质纤维网络的质量。在关节炎中,这种胶原蛋白网络被破坏,导致失去正常的关节功能和剧烈的疼痛。这项研究的目的是开发和鉴定一种生物标志物,以监测在生物工程软骨中组装的胶原异质纤维网络是否为正常软骨的典型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RUSSELL J FERNANDES其他文献

RUSSELL J FERNANDES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RUSSELL J FERNANDES', 18)}}的其他基金

Collagen Assembly in Tissue-Engineered Cartilage
组织工程软骨中的胶原蛋白组装
  • 批准号:
    8053852
  • 财政年份:
    2010
  • 资助金额:
    $ 30.33万
  • 项目类别:
Collagen Assembly in Tissue-Engineered Cartilage
组织工程软骨中的胶原蛋白组装
  • 批准号:
    8450133
  • 财政年份:
    2010
  • 资助金额:
    $ 30.33万
  • 项目类别:
Collagen Assembly in Intervertebral disc
椎间盘中的胶原蛋白组装
  • 批准号:
    9753934
  • 财政年份:
    2010
  • 资助金额:
    $ 30.33万
  • 项目类别:
Collagen Assembly in Tissue-Engineered Cartilage
组织工程软骨中的胶原蛋白组装
  • 批准号:
    7897563
  • 财政年份:
    2010
  • 资助金额:
    $ 30.33万
  • 项目类别:
Collagen Assembly in Intervertebral disc
椎间盘中的胶原蛋白组装
  • 批准号:
    10237287
  • 财政年份:
    2010
  • 资助金额:
    $ 30.33万
  • 项目类别:
Collagen type II/IX/XI heteropolymer assembly
II/IX/XI 型胶原蛋白杂聚物组装体
  • 批准号:
    6965219
  • 财政年份:
    2005
  • 资助金额:
    $ 30.33万
  • 项目类别:
Collagen type II/IX/XI heteropolymer assembly
II/IX/XI 型胶原蛋白杂聚物组装体
  • 批准号:
    7087978
  • 财政年份:
    2005
  • 资助金额:
    $ 30.33万
  • 项目类别:
Collagen type II/IX/XI heteropolymer assembly
II/IX/XI 型胶原蛋白杂聚物组装体
  • 批准号:
    7242645
  • 财政年份:
    2005
  • 资助金额:
    $ 30.33万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.33万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了